ACTIVITY BY QUARTER (variation at current exchange rates)
thousands of euros
1st quarter
2nd quarter
2017
2018
Var. 18/17
2017
2018
Var. 18/17
France
97,134
91,982
-5.3%
79,328
77,199
-2.7%
Europe (excluding France)
40,418
32,899
-18.6%
27,421
24,795
-9.6%
North America
18,179
29,617
+62.9%
14,465
14,958
+3.4%
Other countries
4,532
4,895
+8.0%
3,191
4,185
+31.2%
Group Total
160,263
159,393
-0.5%
124,405
121,137
-2.6%
thousands of euros
1st quarter
2nd quarter
2017
2018
Var. 18/17
2017
2018
Var. 18/17
Non-proprietary Homeopathic Medicines
81,016
76,575
-5.5%
74,567
69,997
-6.1%
OTC Specialties
78,968
82,506
+4.5%
49,391
50,791
+2.8%
Other
279
312
+11.8%
447
349
-21.9%
Group Total
160,263
159,393
-0.5%
124,405
121,137
-2.6%
HIGHLIGHTS OF THE SECOND QUARTER 2018
Sales revenue of the second quarter decreased by 2.6% (1% at constant rate) in comparison to the second quarter of 2017. This decrease is mainly due to a regression of activity in France, Italy and Romania and to a growth in Russia and in North America.
The establishment of Levallois-Perret was sold on June 6, 2018, generating a profit of € 6.2 million.
The company has bought back 831 309 own shares as of June 30, 2018 in accordance with the provisions of the program authorized by the Shareholders' Meeting of May 17, 2018.
Given the slowdown in activity, operating income for the first half of 2018 should be lower than in 2017. Consequently and in the event of a weak pathology at the end of the year, operating income for 2018 could be down compared to 2017.
We carry on the development of homeopathy in the world with the same confidence and the same determination.
Laboratoire BOIRON
Our next update:
September 5, 2018: at market close, publication of 2018 half-year results.
Person responsible for financial information: Christian Boiron.
Contact for financial information: Véronique Bouscayrol.
Investor relations: +33 (0) 4.78.45.63.43 - e-mail : boironfinances@boiron.fr
ISIN Code: FR0000061129 (BOI) - Bloomberg : BOI FP - Reuters : BOIR.PA
The group's financial information and the glossary are online at: www.boironfinance.com
Regulated information
News releases under ongoing reporting obligations:
- News release on accounts, results
Full and original press release in PDF:
https://www.actusnews.com/documents_communiques/ACTUS-0-54328-boi-190718-ca-t2-18-gb.pdf
Receive by email the next press releases of the company by registering on
www.actusnews.com, it′s free
Laboratoires BOIRON was founded in France almost a century ago, under the impetus of homeopathic doctors who wanted to benefit from the most reliable medicines possible. Homeopathic medicines have many advantages in that they can be prescribed and advised in first line whenever relevant, in both urban and hospital settings. All actions aim to contribute to major public health issues.
Homeopathic medicines are obtained from substances called homeopathic strains, according to a manufacturing process described in the pharmacopoeia. These strains can be of plant, animal, mineral or chemical origin.
There are two main families of homeopathic medicines: common name homeopathic medicines and brand name homeopathic medicines (specialties).
BOIRON group centralizes its production and logistics in France. It also has 26 wholly-owned or leased distribution facilities in France and various offices in the countries where it has subsidiaries.
Net sales are distributed geographically as follows: France (52.4%), Europe (22.5%), North America (22.6%) and other (2.5%).
BOIRON 
